Developing a broad pipeline of medical dermatology products


Program Areas & Pipeline

Azitra is using its Microbiome Dermatology Platform to develop products to improve skin appearance and treat skin diseases through three program areas:


Program Area #1: Consumer Products

Azitra’s technology can be applied to address many consumer needs related to skin appearance. Such products will be applied as topical ointments and creams to address conditions including: dry, red, flaky or inflammed skin.

Azitra and Bayer have formed a joint development program targeted at harnessing the human skin microbiome as a source for new natural skin care products for sensitive and eczema-prone skin. To learn more about the collaboration, read the press release here.


Program Area #2: Live BioTherapeutic Products (LBP’s) for Treating Skin Disease

Azitra is using the natural commensal bacteria Staphylococcus epidermidis (SE) from the skin microbiome to develop bioengineered microbiome products for the treatment of skin disease.



Program Area #3: Advanced Technology Indications based on the Microbiome

Azitra has received grant funding from U.S. Department of Defense (DoD) and other agencies to develop advanced microbiome products for military, public health and consumer applications. The overall program includes candidates that target Staph aureus (including MRSA) to reduce potential for mosquito biting and consequently reduce the potential of mosquitos to promote disease vectoring. The Company is also studying the use of commensal bacteria for use as biosensors which may have application in targeting adverse organisms that may attack the skin and potentially for use to counter bio-hazards.

Bioactive compounds derived from skin commensals

A deep dive into how commensal bacteria work may identify bioactive compounds that could provide additional solutions to skin diseases with limited treatment options. It could also ultimately lead to a new class of antimicrobials, which would be particularly valuable in the midst of growing antibiotic resistance.

Azitra maintains a robust research program investigating the bioactive compounds within the skin microbiome. The potential of microbe-based medicine has attracted significant investment from private investors and the government, including a grant from the U.S. Department of Defense to explore the ability of Staphylococcus epidermidis (SE) to inhibit Staphylococcus aureus (SA), which has become resistant to traditional antibiotics. In collaboration with scientists at the Jackson Laboratory in Farmington, CT, we are also characterizing the native antibiotics produced by SE and engineering strains of SE to produce therapeutic levels of those bioactive compounds that can be applied to the skin. If successful, this platform could be extended beyond SE and SA as a broader tool for novel antibiotic discovery


Our skin microbiome plays a crucial role in maintaining human health

Azitra is leveraging the microbiome to solve the challenges of skin disease and adverse skin conditions through three strategies:

Learn more